Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

Name: Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
SKU: 8005
Availability: InStock

$0.00

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

By Henry A. Nasrallah, Ralph Aquila, Arielle D. Stanford, Hasan H. Jamal, Peter J. Weiden, Robert Risinger

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 47 No. 3 Articles - 2017 Tags: antipsychotic-agents, arielle-d-stanford, aripiprazole, aripiprazole-lauroxil, blood-glucose, cholesterol, fasting, hasan-h-jamal, henry-a-nasrallah, peter-j-weiden, prolactin, psychopharmacology, ralph-aquila, robert-risinger, schizophrenia

Description

Description

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

By Henry A. Nasrallah, Ralph Aquila, Arielle D. Stanford, Hasan H. Jamal, Peter J. Weiden, Robert Risinger

35-43_PB-47-3-2017_Nasrallah

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

Description

George Harrison, MD: Priapism and Quetiapine: A Case Report

Genetics of Schizophrenia: Recent Advances

Treatment with Olanzapine: Early Predictors of Weight Gain Risk

Gender and Schizophrenia

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

Description

Related products

George Harrison, MD: Priapism and Quetiapine: A Case Report

Genetics of Schizophrenia: Recent Advances

Treatment with Olanzapine: Early Predictors of Weight Gain Risk

Gender and Schizophrenia